The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease

Márquez-Martín, Eduardo; Admetlló, Mireia; Agustí, Àlvar; Álvarez-Martínez, Carlos J.; Barreiro, Esther; Casadevall, Carme; Casals, Ferrán; Castelo, Robert; Castro-Acosta, Ady; Córdova, Rocío; Cosío, Borja G.; Faner, Rosa; Furlong, Laura I.; García, M T Moros; Gea, Joaquim; González-García, Jose Gregorio; Hernández-Carcereny, Carmen; Lόpez-Campos, José Luís; Márquez, Eduardo; Monsó, Eduard; Montón, Concepción; Ormaza, Miren Josune; Palou, Alexandre; Pascual, Sergi; Peces-Barba, Germán; Puigdevall, Pau; Sanz, Ferrán; Seijó, Luis; Torà, Montserrat; Torralba, Yolanda; Vilaplana, Carles

doi:10.1016/j.arbr.2018.12.010

Cited by 11 publications

(13 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All the individuals were current or former smokers, with preserved ratio between the forced expiratory volume in one second and the forced vital capacity FEV 1 /FVC (controls) or with COPD (cases, FEV 1 /FVC < 0.7) (Table 1). All the individuals were recruited from the centers participating in the CIBERES COPD research program in Spain (19)(20)(21). All the participants signed their informed consent, and the Ethics Committee of Hospital Clinic (Barcelona, Spain) approved the study (HCB-2018/135).…”

Section: Study Population and Ethicsmentioning

confidence: 99%

Telomere Length but Not Mitochondrial DNA Copy Number Is Altered in Both Young and Old COPD

et al. 2021

Self Cite

View full text Add to dashboard Cite

Accelerated ageing is implicated in the pathogenesis of respiratory diseases as chronic obstructive pulmonary disease (COPD), but recent evidence indicates that the COPD can have roots early in life. Here we hypothesise that the accelerated ageing markers might have a role in the pathobiology of young COPD. The objective of this study was to compare two hallmarks of ageing, telomere length (TL), and mitochondrial DNA copy number (mtDNA-CN, as a surrogate marker of mitochondrial dysfunction) in young (≤ 50 years) and old (>50 years) smokers, with and without COPD. Both, TL and mtDNA-CN were measured in whole blood DNA by quantitative PCR [qPCR] in: (1) young ever smokers with (n = 81) or without (n = 166) COPD; and (2) old ever smokers with (n = 159) or without (n = 29) COPD. A multivariable linear regression was used to assess the association of TL and mtDNA-CN with lung function. We observed that in the entire study population, TL and mtDNA-CN decreased with age, and the former but not the latter related to FEV1/FVC (%), FEV1 (% ref.), and DLCO (% ref.). The short telomeres were found both in the young and old patients with severe COPD (FEV1 <50% ref.). In addition, we found that TL and mtDNA-CN were significantly correlated, but their relationship was positive in younger while negative in the older patients with COPD, suggesting a mitochondrial dysfunction. We conclude that TL, but not mtDNA-CN, is associated with the lung function impairment. Both young and old patients with severe COPD have evidence of accelerated ageing (shorter TL) but differ in the direction of the correlation between TL and mtDNA-CN in relation to age.

show abstract

Section: Study Population and Ethicsmentioning

confidence: 99%

Telomere Length but Not Mitochondrial DNA Copy Number Is Altered in Both Young and Old COPD

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…Probably multi-omics and advanced bioinformatics will be able to provide us a more comprehensive and understandable picture that will allow the identification of new therapeutic targets [25] (figure 2). Of note, there are research consortia dedicated to answering this question [26][27][28] that will shed some light in the next decade.…”

Section: Will We Be Able To Unravel the Endotype-phenotype Black Box?mentioning

confidence: 99%

Ten Research Questions for Improving COPD Care in the Next Decade

Lόpez-Campos

Rodríguez

Quintana‐Gallego

et al. 2019

COPD: Journal of Chronic Obstructive Pulmonary Disease

Self Cite

View full text Add to dashboard Cite

With the 60th anniversary of the CIBA symposium, it is worth evaluating research questions that should be prioritized in the future. Coming research initiatives can be summarized in main areas. 1. From epidemiology the impact of new forms of electronic cigarettes on prevalence and mortality of COPD will be sought. 2. The study of the disease endotypes and its relationship phenotypes will have to be unraveled in the next decade. 3. Diagnosis of COPD faces several challenges opening the possibility of a change in the definition of the disease itself. 4. Patients' classification and risk stratification will need to be clarified and reassessed. 5. The asthma-COPD overlap dilemma will have to be clarified and define whether both conditions represent one only chronic airway disease again. 6. Integrating comorbidities in COPD care will be key in a progressively ageing population to improve clinical care in a chronic care model. 7. Non-pharmacological management have areas for research including pulmonary rehabilitation and vaccines. 8. Improving physical activity should focus research because of the clear prognostic impact. 9. Pharmacological therapies present several challenges including efficacy and safety issues with current medications and the development of biological therapy. 10. The definition, identification, categorization and specific therapy of exacerbations will also be an area of research development.During the next decade we have a window of opportunity to address these research questions that will put us on the path for precision medicine.

show abstract

“…Disuse muscle atrophy is an important condition that is the result of progression of other chronic and acute diseases, such as cardiac and respiratory disorders; cancer; prolonged bed rest; and critical illness. Reduced physical activity leading to deconditioning is characterized by the loss of muscle mass and function in the affected muscles in patients [ 1 , 2 , 3 , 4 , 5 ] and in animal models [ 6 , 7 , 8 ]. Muscle atrophy resulting from deconditioning may also worsen disease prognosis in patients with chronic and acute diseases regardless of the underlying condition [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Satellite Cells and Markers of Muscle Regeneration during Unloading and Reloading: Effects of Treatment with Resveratrol and Curcumin

et al. 2020

Self Cite

View full text Add to dashboard Cite

We hypothesized that treatment with pharmacological agents known to increase sirtuin-1 activity (resveratrol and curcumin) may enhance muscle regeneration. In limb muscles of mice (C57BL/6J, 10 weeks) exposed to reloading for seven days following a seven-day period of hindlimb immobilization with/without curcumin or resveratrol treatment, progenitor muscle cell numbers (FACS), satellite cell subtypes (histology), early and late muscle regeneration markers, phenotype and morphometry, sirtuin-1 activity and content, and muscle function were assessed. Treatment with either resveratrol or curcumin in immobilized muscles elicited a significant improvement in numbers of progenitor, activated, quiescent, and total counts of muscle satellite cells, compared to non-treated animals. Treatment with either resveratrol or curcumin in reloaded muscles compared to non-treated mice induced a significant improvement in the CSA of both hybrid (curcumin) and fast-twitch fibers (resveratrol), sirtuin-1 activity (curcumin), sirtuin-1 content (resveratrol), and counts of progenitor muscle cells (resveratrol). Treatment with the pharmacological agents resveratrol and curcumin enhanced the numbers of satellite cells (muscle progenitor, quiescent, activated, and total satellite cells) in the unloaded limb muscles but not in the reloaded muscles. These findings have potential clinical implications as treatment with these phenolic compounds would predominantly be indicated during disuse muscle atrophy to enhance the muscle regeneration process.

show abstract

The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease

Cited by 11 publications

References 32 publications

Telomere Length but Not Mitochondrial DNA Copy Number Is Altered in Both Young and Old COPD

Telomere Length but Not Mitochondrial DNA Copy Number Is Altered in Both Young and Old COPD

Ten Research Questions for Improving COPD Care in the Next Decade

Satellite Cells and Markers of Muscle Regeneration during Unloading and Reloading: Effects of Treatment with Resveratrol and Curcumin

Contact Info

Product

Resources

About